Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Tricuspid regurgitation (TR) is common in patients with atrial functional mitral regurgitation (AFMR) but its impact is not ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...